A Prediction Model of Tumor Progression and Survival in HER2-Positive Metastatic Gastric Cancer Patients Treated with Trastuzumab and Chemotherapy
The effects of different patient factors and dose levels of chemotherapeutic agents on clinical outcomes in advanced gastric cancer are not as yet fully characterized. We aimed at developing an integrative model that incorporates dose and covariate information to predict tumor growth and patient sur...
Gespeichert in:
| Veröffentlicht in: | The AAPS journal 2018-07, Vol.20 (4), p.72-72, Article 72 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 72 |
|---|---|
| container_issue | 4 |
| container_start_page | 72 |
| container_title | The AAPS journal |
| container_volume | 20 |
| creator | Chae, Dongwoo Nam, Chung Mo Kim, Joo Hoon Lee, Choong-Kun Kim, Seung-Seob Kim, Hyo Song Jung, Minkyu Cheong, Jae Ho Chung, Hyun Cheol Rha, Sun Young Park, Kyungsoo |
| description | The effects of different patient factors and dose levels of chemotherapeutic agents on clinical outcomes in advanced gastric cancer are not as yet fully characterized. We aimed at developing an integrative model that incorporates dose and covariate information to predict tumor growth and patient survival in advanced gastric cancer patients treated with trastuzumab (T), 5-FU(F)/capecitabine (X) (F or X), and cisplatin (P). Sixty-nine patients (training dataset) were used for model building and a separate 86 patients (test dataset) for model validation. A fraction of tumor cells sensitive to each drug was incorporated as a model parameter, and T was assumed as cytostatic and X/F and P as cytotoxic. Cox proportional hazards analyses were performed on model parameters and patient covariates. The model well described the time course of observed tumor size changes, and revealed that the pretreatment tumor growth rate constant
k
g
, which was formulated as a function of pretreatment disease duration and baseline tumor size, was positively correlated with baseline tumor size (
p
= 0.0084) and histologic grade (
p
= 0.034), and the efficacy of 5-FU with body weight (
p
|
| doi_str_mv | 10.1208/s12248-018-0223-8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2047257411</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2047257411</sourcerecordid><originalsourceid>FETCH-LOGICAL-c296t-e66350b19815a690de443e3de783dec1cdbf3cf7d186eaf2a0e32c5ed64dc993</originalsourceid><addsrcrecordid>eNp9UctOwzAQtBCIQuEDuCAfuQT8SNLkWFWlRQKBoHfLtTetqyQutlNUPoMvxqWAOHHwPjyzI-0OQheUXFNGihtPGUuLhND4GONJcYBOaJaRZJDS_PBP3UOn3q8I4YxTeox6rCzSjLPyBH0M8ZMDbVQwtsUPVkONbYVnXWNdROzCgfc7SLYav3RuYzayxqbF0_EzS56sN8FsAD9AkD7IYBSexMLFPJKtgqgRP6ENHs8cyAAav5mwjE1kde9dI-dfyqMlNDYswcn19gwdVbL2cP6d-2h2O56Npsn94-RuNLxPFCvzkECe84zMaVnQTOYl0ZCmHLiGQRGDokrPK66qgaZFDrJikgBnKgOdp1qVJe-jq73s2tnXDnwQjfEK6lq2YDsvGEkHLIvXo5FK91TlrPcOKrF2ppFuKygROyfE3gkRnRA7J0QRZy6_5bt5A_p34uf0kcD2BB-hdgFOrGzn2rjxP6qfnT6Wbw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2047257411</pqid></control><display><type>article</type><title>A Prediction Model of Tumor Progression and Survival in HER2-Positive Metastatic Gastric Cancer Patients Treated with Trastuzumab and Chemotherapy</title><source>SpringerLink Journals - AutoHoldings</source><creator>Chae, Dongwoo ; Nam, Chung Mo ; Kim, Joo Hoon ; Lee, Choong-Kun ; Kim, Seung-Seob ; Kim, Hyo Song ; Jung, Minkyu ; Cheong, Jae Ho ; Chung, Hyun Cheol ; Rha, Sun Young ; Park, Kyungsoo</creator><creatorcontrib>Chae, Dongwoo ; Nam, Chung Mo ; Kim, Joo Hoon ; Lee, Choong-Kun ; Kim, Seung-Seob ; Kim, Hyo Song ; Jung, Minkyu ; Cheong, Jae Ho ; Chung, Hyun Cheol ; Rha, Sun Young ; Park, Kyungsoo</creatorcontrib><description>The effects of different patient factors and dose levels of chemotherapeutic agents on clinical outcomes in advanced gastric cancer are not as yet fully characterized. We aimed at developing an integrative model that incorporates dose and covariate information to predict tumor growth and patient survival in advanced gastric cancer patients treated with trastuzumab (T), 5-FU(F)/capecitabine (X) (F or X), and cisplatin (P). Sixty-nine patients (training dataset) were used for model building and a separate 86 patients (test dataset) for model validation. A fraction of tumor cells sensitive to each drug was incorporated as a model parameter, and T was assumed as cytostatic and X/F and P as cytotoxic. Cox proportional hazards analyses were performed on model parameters and patient covariates. The model well described the time course of observed tumor size changes, and revealed that the pretreatment tumor growth rate constant
k
g
, which was formulated as a function of pretreatment disease duration and baseline tumor size, was positively correlated with baseline tumor size (
p
= 0.0084) and histologic grade (
p
= 0.034), and the efficacy of 5-FU with body weight (
p
< 2e−16) and that of cisplatin with histologic grade (
p
= 0.00013). Prior gastrectomy and Eastern Cooperative Oncology Group scores were significant prognostic factors for progression-free survival (PFS). For hazards analysis, a unit increase of
k
g
was associated with a relative risk of 3.19 for PFS (
p
= 0.00055) and 4.45 for OS (
p
= 2e−04) in the test dataset, with a similar trend observed in the training dataset. Dose-response simulations showed that, for small baseline tumor size or low histologic grade, a maximum cytotoxic effect was attainable with a dose smaller than the current recommended dose.</description><identifier>ISSN: 1550-7416</identifier><identifier>EISSN: 1550-7416</identifier><identifier>DOI: 10.1208/s12248-018-0223-8</identifier><identifier>PMID: 29845329</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Biochemistry ; Biomedical and Life Sciences ; Biomedicine ; Biotechnology ; Pharmacology/Toxicology ; Pharmacy ; Research Article</subject><ispartof>The AAPS journal, 2018-07, Vol.20 (4), p.72-72, Article 72</ispartof><rights>American Association of Pharmaceutical Scientists 2018</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c296t-e66350b19815a690de443e3de783dec1cdbf3cf7d186eaf2a0e32c5ed64dc993</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1208/s12248-018-0223-8$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1208/s12248-018-0223-8$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29845329$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chae, Dongwoo</creatorcontrib><creatorcontrib>Nam, Chung Mo</creatorcontrib><creatorcontrib>Kim, Joo Hoon</creatorcontrib><creatorcontrib>Lee, Choong-Kun</creatorcontrib><creatorcontrib>Kim, Seung-Seob</creatorcontrib><creatorcontrib>Kim, Hyo Song</creatorcontrib><creatorcontrib>Jung, Minkyu</creatorcontrib><creatorcontrib>Cheong, Jae Ho</creatorcontrib><creatorcontrib>Chung, Hyun Cheol</creatorcontrib><creatorcontrib>Rha, Sun Young</creatorcontrib><creatorcontrib>Park, Kyungsoo</creatorcontrib><title>A Prediction Model of Tumor Progression and Survival in HER2-Positive Metastatic Gastric Cancer Patients Treated with Trastuzumab and Chemotherapy</title><title>The AAPS journal</title><addtitle>AAPS J</addtitle><addtitle>AAPS J</addtitle><description>The effects of different patient factors and dose levels of chemotherapeutic agents on clinical outcomes in advanced gastric cancer are not as yet fully characterized. We aimed at developing an integrative model that incorporates dose and covariate information to predict tumor growth and patient survival in advanced gastric cancer patients treated with trastuzumab (T), 5-FU(F)/capecitabine (X) (F or X), and cisplatin (P). Sixty-nine patients (training dataset) were used for model building and a separate 86 patients (test dataset) for model validation. A fraction of tumor cells sensitive to each drug was incorporated as a model parameter, and T was assumed as cytostatic and X/F and P as cytotoxic. Cox proportional hazards analyses were performed on model parameters and patient covariates. The model well described the time course of observed tumor size changes, and revealed that the pretreatment tumor growth rate constant
k
g
, which was formulated as a function of pretreatment disease duration and baseline tumor size, was positively correlated with baseline tumor size (
p
= 0.0084) and histologic grade (
p
= 0.034), and the efficacy of 5-FU with body weight (
p
< 2e−16) and that of cisplatin with histologic grade (
p
= 0.00013). Prior gastrectomy and Eastern Cooperative Oncology Group scores were significant prognostic factors for progression-free survival (PFS). For hazards analysis, a unit increase of
k
g
was associated with a relative risk of 3.19 for PFS (
p
= 0.00055) and 4.45 for OS (
p
= 2e−04) in the test dataset, with a similar trend observed in the training dataset. Dose-response simulations showed that, for small baseline tumor size or low histologic grade, a maximum cytotoxic effect was attainable with a dose smaller than the current recommended dose.</description><subject>Biochemistry</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Biotechnology</subject><subject>Pharmacology/Toxicology</subject><subject>Pharmacy</subject><subject>Research Article</subject><issn>1550-7416</issn><issn>1550-7416</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp9UctOwzAQtBCIQuEDuCAfuQT8SNLkWFWlRQKBoHfLtTetqyQutlNUPoMvxqWAOHHwPjyzI-0OQheUXFNGihtPGUuLhND4GONJcYBOaJaRZJDS_PBP3UOn3q8I4YxTeox6rCzSjLPyBH0M8ZMDbVQwtsUPVkONbYVnXWNdROzCgfc7SLYav3RuYzayxqbF0_EzS56sN8FsAD9AkD7IYBSexMLFPJKtgqgRP6ENHs8cyAAav5mwjE1kde9dI-dfyqMlNDYswcn19gwdVbL2cP6d-2h2O56Npsn94-RuNLxPFCvzkECe84zMaVnQTOYl0ZCmHLiGQRGDokrPK66qgaZFDrJikgBnKgOdp1qVJe-jq73s2tnXDnwQjfEK6lq2YDsvGEkHLIvXo5FK91TlrPcOKrF2ppFuKygROyfE3gkRnRA7J0QRZy6_5bt5A_p34uf0kcD2BB-hdgFOrGzn2rjxP6qfnT6Wbw</recordid><startdate>20180701</startdate><enddate>20180701</enddate><creator>Chae, Dongwoo</creator><creator>Nam, Chung Mo</creator><creator>Kim, Joo Hoon</creator><creator>Lee, Choong-Kun</creator><creator>Kim, Seung-Seob</creator><creator>Kim, Hyo Song</creator><creator>Jung, Minkyu</creator><creator>Cheong, Jae Ho</creator><creator>Chung, Hyun Cheol</creator><creator>Rha, Sun Young</creator><creator>Park, Kyungsoo</creator><general>Springer International Publishing</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20180701</creationdate><title>A Prediction Model of Tumor Progression and Survival in HER2-Positive Metastatic Gastric Cancer Patients Treated with Trastuzumab and Chemotherapy</title><author>Chae, Dongwoo ; Nam, Chung Mo ; Kim, Joo Hoon ; Lee, Choong-Kun ; Kim, Seung-Seob ; Kim, Hyo Song ; Jung, Minkyu ; Cheong, Jae Ho ; Chung, Hyun Cheol ; Rha, Sun Young ; Park, Kyungsoo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c296t-e66350b19815a690de443e3de783dec1cdbf3cf7d186eaf2a0e32c5ed64dc993</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Biochemistry</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Biotechnology</topic><topic>Pharmacology/Toxicology</topic><topic>Pharmacy</topic><topic>Research Article</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chae, Dongwoo</creatorcontrib><creatorcontrib>Nam, Chung Mo</creatorcontrib><creatorcontrib>Kim, Joo Hoon</creatorcontrib><creatorcontrib>Lee, Choong-Kun</creatorcontrib><creatorcontrib>Kim, Seung-Seob</creatorcontrib><creatorcontrib>Kim, Hyo Song</creatorcontrib><creatorcontrib>Jung, Minkyu</creatorcontrib><creatorcontrib>Cheong, Jae Ho</creatorcontrib><creatorcontrib>Chung, Hyun Cheol</creatorcontrib><creatorcontrib>Rha, Sun Young</creatorcontrib><creatorcontrib>Park, Kyungsoo</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The AAPS journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chae, Dongwoo</au><au>Nam, Chung Mo</au><au>Kim, Joo Hoon</au><au>Lee, Choong-Kun</au><au>Kim, Seung-Seob</au><au>Kim, Hyo Song</au><au>Jung, Minkyu</au><au>Cheong, Jae Ho</au><au>Chung, Hyun Cheol</au><au>Rha, Sun Young</au><au>Park, Kyungsoo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Prediction Model of Tumor Progression and Survival in HER2-Positive Metastatic Gastric Cancer Patients Treated with Trastuzumab and Chemotherapy</atitle><jtitle>The AAPS journal</jtitle><stitle>AAPS J</stitle><addtitle>AAPS J</addtitle><date>2018-07-01</date><risdate>2018</risdate><volume>20</volume><issue>4</issue><spage>72</spage><epage>72</epage><pages>72-72</pages><artnum>72</artnum><issn>1550-7416</issn><eissn>1550-7416</eissn><abstract>The effects of different patient factors and dose levels of chemotherapeutic agents on clinical outcomes in advanced gastric cancer are not as yet fully characterized. We aimed at developing an integrative model that incorporates dose and covariate information to predict tumor growth and patient survival in advanced gastric cancer patients treated with trastuzumab (T), 5-FU(F)/capecitabine (X) (F or X), and cisplatin (P). Sixty-nine patients (training dataset) were used for model building and a separate 86 patients (test dataset) for model validation. A fraction of tumor cells sensitive to each drug was incorporated as a model parameter, and T was assumed as cytostatic and X/F and P as cytotoxic. Cox proportional hazards analyses were performed on model parameters and patient covariates. The model well described the time course of observed tumor size changes, and revealed that the pretreatment tumor growth rate constant
k
g
, which was formulated as a function of pretreatment disease duration and baseline tumor size, was positively correlated with baseline tumor size (
p
= 0.0084) and histologic grade (
p
= 0.034), and the efficacy of 5-FU with body weight (
p
< 2e−16) and that of cisplatin with histologic grade (
p
= 0.00013). Prior gastrectomy and Eastern Cooperative Oncology Group scores were significant prognostic factors for progression-free survival (PFS). For hazards analysis, a unit increase of
k
g
was associated with a relative risk of 3.19 for PFS (
p
= 0.00055) and 4.45 for OS (
p
= 2e−04) in the test dataset, with a similar trend observed in the training dataset. Dose-response simulations showed that, for small baseline tumor size or low histologic grade, a maximum cytotoxic effect was attainable with a dose smaller than the current recommended dose.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>29845329</pmid><doi>10.1208/s12248-018-0223-8</doi><tpages>1</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1550-7416 |
| ispartof | The AAPS journal, 2018-07, Vol.20 (4), p.72-72, Article 72 |
| issn | 1550-7416 1550-7416 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2047257411 |
| source | SpringerLink Journals - AutoHoldings |
| subjects | Biochemistry Biomedical and Life Sciences Biomedicine Biotechnology Pharmacology/Toxicology Pharmacy Research Article |
| title | A Prediction Model of Tumor Progression and Survival in HER2-Positive Metastatic Gastric Cancer Patients Treated with Trastuzumab and Chemotherapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T01%3A06%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Prediction%20Model%20of%20Tumor%20Progression%20and%20Survival%20in%20HER2-Positive%20Metastatic%20Gastric%20Cancer%20Patients%20Treated%20with%20Trastuzumab%20and%20Chemotherapy&rft.jtitle=The%20AAPS%20journal&rft.au=Chae,%20Dongwoo&rft.date=2018-07-01&rft.volume=20&rft.issue=4&rft.spage=72&rft.epage=72&rft.pages=72-72&rft.artnum=72&rft.issn=1550-7416&rft.eissn=1550-7416&rft_id=info:doi/10.1208/s12248-018-0223-8&rft_dat=%3Cproquest_cross%3E2047257411%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2047257411&rft_id=info:pmid/29845329&rfr_iscdi=true |